Clik here to view.
Treating metastatic prostate cancer in very elderly men: a review
A helpful review article on the treatment of metastatic and metastatic, castration-resistant prostate cancer (mCRPC) in very elderly men appears in last month’s issue of Clinical Interventions in...
View ArticleClik here to view.
A possible new opportunity for treatment of advanced, neuroendocrine forms of...
An article by Strosberg et al. in today’s issue of the New England Journal of Medicine has nothing to do with prostate cancer at all; it’s all about a new form of treatment for certain types of...
View ArticleClik here to view.
Iodine-131-MIP-1095, a new radiopharmaceutical, in clinical trials at MSKCC
There are few radiopharmaceuticals in clinical trials in the US (although there are several in use in Germany), so when a new one is announced, we take notice. Iodine-131-MIP-1095 (1-131-MIP-1095) has...
View ArticleClik here to view.
Another research team, and another micro-RNA …
Last week we mentioned that one specific form of micro-ribonucleic acid (miRNA) may be usable in the development of a drug or drugs to stop the process of metastasis in men with high-risk forms of...
View ArticleClik here to view.
The impact of emotional distress on prostate cancer decision-making
According to a newly published paper in the Journal of Urology, Emotional distress may motivate men with low risk prostate cancer to choose more aggressive treatment. Addressing emotional distress...
View ArticleClik here to view.
Risk, prostate cancer, and being 70 to 80 years of age
So a relatively new article in Reviews in Urology caught your Sitemaster’s eye this morning — and worried him because it seemed to be communicating a conclusion of questionable accuracy, which we will...
View ArticleClik here to view.
A high-grade ego with high-grade prostate cancer
For those who have either forgotten or never knew who Craig Venter is or was, here’s an update: he recently had surgical treatment for “high-grade” prostate cancer. And with his usual high capacity for...
View ArticleClik here to view.
Decision making and the treatment of localized prostate cancer today
This month’s issue of Urologic Oncology contains a series of six articles that may be of particular interest to prostate cancer support group leaders and other prostate cancer educators. Rather than...
View ArticleClik here to view.
What’s good for the patient is not always what they want
The following article was originally published in the ASCO Connection magazine on February 22, 2017 (click here for the original). It was written by Anne Katz, RN, PhD, FAAN, who is a certified...
View ArticleClik here to view.
Current trends in the management of oligometastatic prostate cancer
In what one of the authors has described as “a somewhat critical and light-hearted look at our current enthusiasm for aggressive approaches to oligometastatic prostate cancer”, an article currently in...
View ArticleClik here to view.
Finding common ground on how “best” to treat localized prostate cancer, and...
One of the hardest issues for newly diagnosed prostate cancer patients to deal with has long been the differences in opinion between physicians about appropriate first-line treatment (and the relevant...
View ArticleClik here to view.
US-based, Phase II trial of lutetium-177 PSMA-directed endoradiotherapy
We have been provided (by the developers) with additional information about a US-based, Phase II, clinical trial of a form of radiation therapy using the targeted agent lutetium-177 prostate-specific...
View ArticleClik here to view.
Revised ASCO/CCO brachytherapy guidelines
The publication of the ASCENDE-RT clinical trial (discussed here) has led to a revision in the brachytherapy guidelines (available here) issued jointly by the American Society of Clinical Oncology...
View ArticleClik here to view.
“Right to try” legislation and the management of prostate cancer
As many of our readers may be aware, the “right to try” treatments using investigational new drugs outside of the clinical trials processes required by drug developers and overseen by the US Food and...
View ArticleClik here to view.
Aggressive, trimodal therapy active in treatment of selected men with M1...
A new report in the journal Urology has shown that a subset of men with metastatic disease can be placed in long-term remission through the use of a combination of androgen deprivation therapy (ADT) +...
View ArticleClik here to view.
New guidance on treatment of localized prostate cancer from AUA and others
Over the weekend, the American Urological Association (AUA), together with the Society for Urologic Oncology (SUO), and the American Society for Radiation Oncology (ASTRO) issued new guidance on the...
View ArticleClik here to view.
Kaiser reports on quality of life outcomes after first-line treatment for...
Kaiser Permanente maintains a large data registry in order to assess the quality of outcomes over time among tens of thousands of Kaiser patients, prostate cancer patients included. In the current...
View ArticleClik here to view.
Brachy boost therapy should be reserved for unfavorable risk patients
The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost...
View ArticleClik here to view.
Should you be adding abiraterone acetate to your ADT?
The data previously reported from the STAMPEDE trial and the LATITUDE trial over the past couple of days were from men newly diagnosed with high-risk and/or metastatic forms of prostate cancer, but …...
View ArticleClik here to view.
Targeted photodynamic therapy for challenging forms of prostate cancer
We already know that linking certain types of radioactive agent to specific forms of prostate-specific membrane antigen (PSMA) offers new opportunities for the treatment of challenging cases of...
View Article